Hair and Nail Adverse Events During Treatment with Targeted Therapies for Metastatic Melanoma

    Emi Dika, Annalisa Patrizi, Simone Ribero … Bianca Maria Piraccini
    Studysummary In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jle.com →
    Discuss this study in the Community →

    Research cited in this study 7

    1. RASopathic Alopecia: Hair Changes Associated with Vemurafenib Therapy Journal of The American Academy of Dermatology · 2015
    2. Cutaneous Adverse Effects of Targeted Therapies Journal of the American Academy of Dermatology · 2015
    3. Evaluation of Hair Loss Current problems in dermatology · 2015
    4. Cutaneous Adverse Effects of BRAF Inhibitors in Metastatic Malignant Melanoma: A Prospective Study in 20 Patients Journal of the European Academy of Dermatology and Venereology · 2014
    5. A Case of Repigmentation and Curling of Hair on Acitretin Therapy Clinical and experimental dermatology · 2013
    6. RASopathic Skin Eruptions During Vemurafenib Therapy PLoS ONE · 2013
    7. Sodium Valproate-Induced Kinky Hair PubMed · 2001

    Related research 1

    1. Hair and Nail Adverse Events During Treatment with Targeted Therapies for Metastatic Melanoma European journal of dermatology/EJD. European journal of dermatology · 2016